When Arnold returned to the company, he gathered the company's scientific apes and described in detail what he saw in the Sinovel lab, and although he omitted the non-disclosure agreement, his description was enough for the researchers to refer to. Pen ~ fun ~ pavilion www.biquge.info

In fact, the confidentiality agreement was originally Yang Rui's precaution, and there was no mysterious information in his laboratory that could be taken away after seeing it.

Arnold finished his description and asked, "Do you think there is hope? ”

After several researchers discussed in a low voice, the new CTO Fan Lunding said: "As far as the current known conditions are concerned, if deferiprone is synthesized, there is no problem with the active substance." As long as the active substance is made, it is necessary to continue to do it. ”

Van Lunding came to replace Trapp, a well-known expert in biology and chemistry who had only come to help when the China region was launched.

Van Lunding is less qualified than a professor at Sheffield, and his most notable achievement is being a Cambridge-born rower who competed in the Olympics, and that's it.

Van Lunding did not have much contact with Yang Rui, so he considered it purely from the scientific aspect, and said: "I don't think it's a good idea to do drug research in China, even if he wants to sell his company at a good price, it's not worth making original drugs." If you take the route of rare drugs, you can indeed save a lot of trouble, but it is still very troublesome and not an appropriate choice. ”

"He has already chosen, I think, the crux of the question should be, do you think Yang Rui can succeed?" Arnold asked very seriously, this is indeed a key question.

Fan Lunding thought for a moment, did not dare to categorically deny, and said: "It's hard to judge, but you know, even if 100 active substances are synthesized, they may not pass animal testing, let alone human clinical trials, and he is still far from success." ”

Other researchers also nodded, saying that they were not optimistic about Yang Rui's research.

The researcher in China is mainly responsible for solving the production problems of the coenzyme Q10 factory, and at the same time helping the Chinese partners to build new factories, and Yang Rui has also dealt with him.

However, they used to see Yang Rui as an academic figure, but now they see him enter the industrial world, and they all reveal the inherent prejudice of industrial people against academic people.

"It is not so easy to develop original drugs, and it is very difficult for Yang Rui to succeed. ”

"It's unlikely to succeed. ”

"Maybe he wants to sell us the active substance he made?"

"You have to pass animal testing before it's worth selling. ”

Arnold listened to their discussion, and also changed some thoughts, and said: "As far as I know, Yang Rui's record is very powerful, and now he is meddling in the deferidone, I'm afraid he has some hole cards." ”

Van Lunding smiled and said, "It's not unusual for every researcher to be confident that they can succeed before starting the experiment. As a result, you see, how many drugs can be successful in the end? There are too many researchers in our company who have a good record, and who can guarantee that their next new drug will be successful. ”

Arnold lowered his head in thought, suddenly made an expression of what he thought of, shook his head, and asked, "Van Lunding, I remember that you used to do new drug development?"

"Yes. ”

"What was the result?"

"The project failed, the company reorganized the project team, failed again, the company reorganized the team, continued to fail, the company made additional investment, still unsuccessful, and the project team was finally disbanded. In the most concise way, Van Lunding described the seven years that once belonged to him.

Arnold looked unaware and asked, "How far have you got?"

"Phase II of clinical trial. ”

"From target screening, to drug synthesis, to animal experiments, and then to clinical phase I and clinical phase II...... It's a bit of a pity to give up at the end of the journey. Arnold doesn't know much about scientific research, but he still knows a lot about project management.

"Although it is a pity, the effectiveness test did not pass, and it will only cost more money to continue. Van Lunding spoke with a blank face from the company's standpoint.

The first phase of a clinical trial is the safety phase of a drug, which is usually conducted in 20 to 40 healthy volunteers and costs less than $1 million.

The second phase of a clinical trial is the effectiveness phase of a drug, which requires 100 to 300 patients and usually costs more than $20 million.

As for the third phase of clinical trials, it is the large-scale verification stage of the safety and efficacy of drugs, since it is large-scale, it is indispensable to a large number of people, in the testing of non-rare drugs, the number of people in the third phase of clinical trials usually increases to 20,000 people, and the cost also reaches a staggering more than 100 million US dollars.

It is conceivable that no company will rush forward with the progress of clinical trials without considerable certainty.

Arnold thought of this, and then thought about what Yang Rui was doing now, he couldn't help but pull Van Lunding aside, and said in a low voice: "You think of a way to let Yang Rui quickly advance the research progress and expand the scale of research, can you do it?"

"Why?" Van Lunding wondered.

"You don't have to manage the reason, just do what I say. Arnold thought and laughed to himself.

The main purpose of his visit to China was to purchase the catalyst formula for coenzyme Q10, and the two-month delay was almost his limit.

However, Yang Rui did not seem to be affected by the time delay, which made Arnold not only frustrated, but worried.

In his opinion, the main reason for this problem is that Yang Rui does not have an urgent thirst for funds.

Yang Rui's biggest expense at present is the cost of attorney's fees, which cost nearly one million US dollars per month, which fully proves the seriousness and child's play of American law, but Jielizene's quarterly dividends of millions of dollars fall into the hands of Yang Rui, which is enough to solve the problem of legal fees.

As a result, Yang Rui naturally has no urge to urgently sell catalyst patents.

However, if Yang Rui invests too much in research on new drugs, things will be completely different.

Arnold is not entirely sure how many shares Yang Rui has in Sinovel Company, but through various understandings, Arnold is sure that Yang Rui has shares. The lawyer who helped Yang Rui establish the company back then was a relationship with Jielikang, although Arnold couldn't ask for specific details, there was always rough news.

Van Lunding didn't understand Arnold's purpose, so he could only say from the perspective of research: "When new drugs are researched, everyone will carefully control the progress and scale of the research......"

"Yang Rui has not done new drug research before, if you go to him and give him advice, he may be able to implement it. ”

"You're going to send me to Sinovel Labs for guidance?"

"Well, help them advance the progress of the experiment and push it faster...... "The initial cost of new drug research is not high, but the cost in the later stage is a bottomless pit.

Van Lunding didn't think it was useful, but he agreed.

The next day, Van Lunding arrives at Sinovel Labs, where he realizes that he seems to have been wrong.

The research progress of Sinovel Labs is far faster than he imagined.

……